LUPIN LIMITED Fair Value
LUPIN · Healthcare · Current price ₹2,143
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹613 | 29% ROE fading to 12% over ~3 yrs, on ₹491 book |
| Relative P/E | ₹4,562 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹1,135 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,486 | Street consensus 12-month target price |
Is LUPIN LIMITED undervalued?
DocStoX estimates the fair value of LUPIN LIMITED at ₹1,927 per share, versus the current market price of ₹2,143. That puts the stock about -10.1% above our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹613), Relative P/E (₹4,562), Graham floor (₹1,135), Analyst target (₹2,486). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹613 (bear) to ₹1,927 (base) to ₹4,562 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on LUPIN LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.